|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.85 USD | +0.34% |
|
-8.34% | -12.59% |
| Apr. 26 | S&P 500 Q1 earnings estimated growth improves; stocks up for week | RE |
| Apr. 26 | Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 | MT |
March 15 (Reuters) - Advisers to the U.S. Food and Drug Administration on Friday voted in favor of allowing the use of Bristol Myers Squibb's cell therapy as an earlier treatment for a type of blood cancer.
The panel voted 8-3 in favor that benefits of Bristol's Abecma outweighed the risks of the therapy when given as an earlier treatment. (Reporting by Bhanvi Satija and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 44.85 USD | +0.34% | -8.34% | 90.92B | ||
| 4.255 USD | -0.82% | -5.86% | 219M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -12.59% | 90.92B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
BRISTOL-MYERS SQUIBB COMPANY 
